Recruiting

Informing Implementation of a Circadian-Focused Intervention for Postpartum Depression

The proposed study is an open-label trial of Re-Timer® wearable morning bright light therapy for postpartum depression. The study is focused on evaluating the feasibility, acceptability, and implementation context of morning Bright Light Treatment (mBLT) for postpartum depression.

I'm interested View official listing
ClinicalTrials.gov IDNCT07766161
PhaseNA
Enrollment30
SponsorUniversity of Michigan
Age18 Years and older
SexFEMALE
I'm interested View official listing

Conditions studied

Postpartum Depression (PPD)

About this study

The proposed study is an open-label trial of Re-Timer® wearable morning bright light therapy for postpartum depression. The study is focused on evaluating the feasibility, acceptability, and implementation context of morning Bright Light Treatment (mBLT) for postpartum depression.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: 1. ≤ 6 months postpartum 2. EPDS score \>10 Exclusion Criteria: 1. Current or past-year substance use disorder 2. Lifetime history of bipolar disorder or psychotic disorder 3. Active suicidal intent 4. Retinal pathology or history of eye surgery 5. Current use of photosensitizing medications 6. Untreated sleep-disordered breathing, untreated restless legs syndrome, or narcolepsy 7. Psychotherapy or psychotropic medications started/dose changed in past month (psychotherapy started and/or current medication at stable dose ≥ 4 weeks are permitted) 8. Medical conditions contraindicated for mBLT (e.g., epilepsy/seizures)

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-19.